Detailed Narrative
Strong Q1 FY27 Performance Driven by Complex Generics
Granules India reported its strongest first quarter ever, with revenue growing 22% year-on-year to ₹1,477 crores. Profit after tax saw a significant 60% increase to ₹180 crores. This robust performance was primarily fueled by complex generics, which now constitute 50% of finished dosages, up from 39% a year ago, demonstrating a successful shift towards a differentiated product portfolio. The company's US manufacturing arm, GPI, has climbed to the 27th position among US generic companies from 74th just five years ago.
Margin Expansion and Healthy Cash Generation
The company achieved a healthy gross margin of 65.6%, expanding by 74 basis points year-on-year, and EBITDA grew 37% to ₹339 crores, with the margin expanding by 256 basis points to 22.9%. This profitability, combined with disciplined working capital management, led to strong operating cash generation of ₹387.4 crores this quarter. The net debt to EBITDA ratio improved significantly to a near-zero 0.07x, indicating a virtually debt-free position, providing comfort to fund future growth.
Peptide CDMO Platform Scaling Up Despite Quarterly Volatility
The peptide CDMO platform, built around Senn, grew over 100% year-on-year, contributing CHF 5 million in Q1 FY27. Despite reporting a negative EBITDA of ₹12 crores this quarter, management clarified this was due to project mix and long cycle times, with value realization expected in later quarters. The company targets an intermediate milestone of $50 million revenue with 30%+ EBITDA margin within the next 3 years and is investing ₹300 crores for infrastructure upgrades and a new peptide facility at Vizag, India.
Regulatory Progress and Robust Product Pipeline
Remediation work at the Gagillapur facility is largely complete, with all FDA responses submitted on time and no concerns raised by the agency. Nine applications are ready to launch pending FDA clearance for this facility. Overall, Granules has 18 approvals still pending, with 9 expected to launch immediately post FDA clearance. The company is also developing 9-13 oncology products, with the first self-developed product slated for launch in FY28-29, aiming to be a significant growth driver.
Strategic Investments in R&D and Capacity Expansion
Capital expenditure for Q1 FY27 was ₹89 crores, with the full-year guidance remaining at ₹600 crores, focusing on digitalization and modular growth projects at existing facilities. R&D expenses increased 30% year-on-year to ₹88 crores, representing 6% of sales, reflecting continued investment in high-barrier areas like CNS, oncology, and complex formulations to build a differentiated product pipeline. The Genome Valley facility is expected to cross 50% utilization by year-end, adding significant formulation capacity.
Working Capital Efficiency and Europe Market Dynamics
The company's working capital to sales improved to 29% in Q1 FY27, down from 30% in Q1 FY26 and Q4 FY26, driven by reduced receivables, particularly in the US market. In Europe, sequential softness was attributed to cost pressures on legacy products, where Granules opted to hold back supply rather than accept unfavorable pricing, indicating a strategic decision to protect margins rather than a decline in demand.